Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVTNASDAQ:MYGNNASDAQ:NEONASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$15.80-0.4%$15.07$12.72▼$34.47$2.71B0.611.22 million shs1.91 million shsMYGNMyriad Genetics$4.92-3.0%$5.55$3.81▼$29.30$467.34M1.841.25 million shs3.16 million shsNEONeoGenomics$7.00+0.7%$8.01$6.08▼$19.12$894.43M1.651.25 million shs2.35 million shsPCRXPacira BioSciences$24.23+0.3%$25.47$11.16▼$29.61$1.12B0.52967,901 shs668,087 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant0.00%-0.50%+5.73%-19.25%-39.44%MYGNMyriad Genetics0.00%-2.31%+13.93%-49.35%-78.79%NEONeoGenomics0.00%-5.95%-13.02%-29.51%-46.58%PCRXPacira BioSciences0.00%-1.23%-9.72%+0.04%-14.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMVTImmunovant0.9331 of 5 stars3.50.00.00.00.01.70.0MYGNMyriad Genetics4.0563 of 5 stars4.11.00.04.12.11.70.6NEONeoGenomics4.0733 of 5 stars4.25.00.00.01.43.31.3PCRXPacira BioSciences2.4545 of 5 stars1.21.00.03.92.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.90Moderate Buy$38.33142.62% UpsideMYGNMyriad Genetics 2.13Hold$14.38192.37% UpsideNEONeoGenomics 2.45Hold$13.8397.62% UpsidePCRXPacira BioSciences 2.33Hold$26.449.14% UpsideCurrent Analyst Ratings BreakdownLatest NEO, MYGN, PCRX, and IMVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025MYGNMyriad GeneticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$20.00 ➝ $6.005/15/2025MYGNMyriad GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.50 ➝ $9.005/15/2025NEONeoGenomicsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral5/9/2025PCRXPacira BioSciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$32.00 ➝ $30.005/8/2025MYGNMyriad GeneticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Peer Perform5/7/2025MYGNMyriad GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$18.005/7/2025MYGNMyriad GeneticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $8.005/7/2025MYGNMyriad GeneticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$19.00 ➝ $10.005/7/2025MYGNMyriad GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$16.00 ➝ $7.005/7/2025MYGNMyriad GeneticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$22.00 ➝ $6.005/6/2025NEONeoGenomicsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$18.00 ➝ $12.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.16 per shareN/AMYGNMyriad Genetics$831.30M0.55$0.97 per share5.07$7.70 per share0.64NEONeoGenomics$660.57M1.36$0.44 per share15.84$7.03 per share1.00PCRXPacira BioSciences$700.97M1.60$4.33 per share5.59$16.86 per share1.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$413.84M-$2.74N/AN/AN/AN/A-80.60%-71.89%8/5/2025 (Estimated)MYGNMyriad Genetics-$127.30M-$1.12N/AN/AN/A-12.20%-4.95%-3.39%8/5/2025 (Estimated)NEONeoGenomics-$78.73M-$0.61N/A77.78N/A-11.54%-2.21%-1.22%8/4/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.28N/A9.43N/A-14.78%13.78%7.00%7/29/2025 (Estimated)Latest NEO, MYGN, PCRX, and IMVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/A$0.16 million5/6/2025Q1 2025MYGNMyriad Genetics-$0.05-$0.03+$0.02N/A$200.37 million$195.90 million4/29/2025Q1 2025NEONeoGenomics-$0.02-$0.08-$0.06-$0.20$171.38 million$168.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/AMYGNMyriad GeneticsN/AN/AN/AN/AN/ANEONeoGenomicsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A11.1611.16MYGNMyriad Genetics0.081.901.71NEONeoGenomics0.382.051.95PCRXPacira BioSciences0.482.411.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%MYGNMyriad Genetics99.02%NEONeoGenomics98.50%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant5.90%MYGNMyriad Genetics2.40%NEONeoGenomics2.40%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120170.92 million160.84 millionOptionableMYGNMyriad Genetics2,70092.18 million89.97 millionOptionableNEONeoGenomics2,200128.70 million125.61 millionOptionablePCRXPacira BioSciences72046.29 million43.33 millionOptionableNEO, MYGN, PCRX, and IMVT HeadlinesRecent News About These CompaniesHead to Head Analysis: Pacira BioSciences (NASDAQ:PCRX) & Antibe Therapeutics (OTCMKTS:ATBPD)June 20 at 2:39 AM | americanbankingnews.comPacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025June 18 at 6:04 PM | finance.yahoo.comIs the Options Market Predicting a Spike in Pacira BioSciences Stock?June 18 at 12:11 PM | zacks.comPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from AnalystsJune 18 at 3:56 AM | marketbeat.comComparing Pacira BioSciences (NASDAQ:PCRX) and I-Mab (NASDAQ:IMAB)June 18 at 2:09 AM | americanbankingnews.comPACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 17 at 9:00 PM | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 14, 2025 | marketbeat.comPacira Pharmaceuticals Stockholders Approve Amended Incentive PlanJune 13, 2025 | tipranks.comBridge City Capital LLC Reduces Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 9, 2025 | marketbeat.comPacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationJune 8, 2025 | accessnewswire.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 21,781 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)June 8, 2025 | marketbeat.comLauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockJune 7, 2025 | insidertrades.comPacira BioSciences (NASDAQ:PCRX) Upgraded at Wall Street ZenJune 7, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) SVP Sells $146,199.38 in StockJune 6, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comWellington Management Group LLP Has $8.86 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 3, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Has $1.72 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 3, 2025 | marketbeat.comTwo Sigma Advisers LP Purchases New Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)June 3, 2025 | marketbeat.comTwo Sigma Investments LP Purchases 45,222 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)June 2, 2025 | marketbeat.comQ3 EPS Estimate for Pacira BioSciences Raised by AnalystJune 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEO, MYGN, PCRX, and IMVT Company DescriptionsImmunovant NASDAQ:IMVT$15.80 -0.06 (-0.38%) Closing price 04:00 PM EasternExtended Trading$15.80 0.00 (0.00%) As of 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Myriad Genetics NASDAQ:MYGN$4.92 -0.15 (-2.96%) Closing price 04:00 PM EasternExtended Trading$4.74 -0.19 (-3.76%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.NeoGenomics NASDAQ:NEO$7.00 +0.05 (+0.72%) Closing price 04:00 PM EasternExtended Trading$7.09 +0.09 (+1.29%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Pacira BioSciences NASDAQ:PCRX$24.23 +0.08 (+0.33%) Closing price 04:00 PM EasternExtended Trading$24.23 0.00 (0.00%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
